A precision health approach to medication management in neurodivergence: a model development and validation study using four international cohorts

Marlee M. Vandewouw[1,2,3], Kamran Niroomand[1], Harshit Bokadia[1], Sophia Lenz[1], Jesiqua Rapley[1], Alfredo Arias[4], Jennifer Crosbie[5,6], Elisabetta Trinari[7], Elizabeth Kelley[8], Robert Nicolson[9], Russell J. Schachar[5,6], Paul D. Arnold[10], Alana Iaboni[1], Jason P. Lerch[11,12,13], Melanie Penner[1], Danielle Baribeau[1,5,6,14,15], Evdokia Anagnostou[1,13,14,16,17], Azadeh Kushki[1,18]

1. Autism Research Center, Bloorview Research Institute, Holland Bloorview Kids Rehabilitation Hospital, Toronto, Canada
2. Center for Precision Psychiatry, Massachusetts General Hospital, Boston, United States of America
3. Department of Psychiatry, Harvard Medical School, Boston, United States of America
4. Province of Ontario Neurodevelopmental Network, Toronto, Canada
5. Department of Psychiatry, The Hospital for Sick Children, Toronto, Canada
6. Department of Psychiatry, University of Toronto, Toronto, Canada
7. Faculty of Health Sciences, McMaster University, Hamilton, Canada
8. Departments of Psychology and Psychiatry, Queen's University, Kingston, Canada
9. Department of Psychiatry, University of Western Ontario, London, Canada
10. Department of Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, Canada
11. Wellcome Centre for Integrative Neuroimaging, FMRIB, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom
12. Department of Medical Biophysics, University of Toronto, Toronto, Canada
13. Program in Neurosciences & Mental Health, The Hospital for Sick Children, Toronto, Canada
14. Institute of Medical Sciences, University of Toronto, Toronto, Canada
15. Institute of Health Policy, Management, and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
16. Department of Paediatrics, University of Toronto, Toronto, Canada
17. Department of Psychiatry, Icahn School of Medicine, Mount Sinai, New York, United States of America
18. Institute of Biomedical Engineering, The University of Toronto, Toronto, Canada

Corresponding author:

Dr. Azadeh Kushki

Bloorview Research Institute

Holland Bloorview Kids Rehabilitation Hospital

150 Kilgour Road Toronto, Ontario M4G 1R8

Tel: 416-425-6220, extension 3563

Keywords: artificial intelligence, medication management, neurodivergence, neurodevelopmental conditions, autism

Summary

Background: Psychotropic medications are commonly used for neurodivergent children, but their

effectiveness varies, making prescribing challenging and potentially exposing individuals to

multiple medication trials. We developed artificial intelligence (AI) models to predict medication

success for stimulants, anti-depressants, and anti-psychotics. We first demonstrate feasibility

using cross-sectional data from three research cohorts, then use a cohort of patients from a

pharmacology clinic to predict medication choice by class, longitudinally, from electronic

medical records (EMRs).

Methods: Models were built to predict cross-sectional medication usage from the Child

Behaviour Checklist. Data from the Province of Ontario Neurodevelopmental (POND) network

(*N*=598) trained and tested the models, while data from the Healthy Brain Network (HBN;

N=1,764) and Adolescent Brain Cognitive Development (ABCD; *N*=2,396) studies were used for

external validation. For the EMR cohort, data from the Psychopharmacology Program (PPP;

N=312) at Holland Bloorview Kids Rehabilitation Hospital were used to predict longitudinal

success. Stacked ensemble models were built separately for each medication class, and area

under the receiving operating characteristic curve (AU-ROC) evaluated performance.

Findings: The research cohorts demonstrated feasibility, with internal testing (POND) achieving

an AU-ROC (mean [95% CI]) of 0.72 [0.71,0.74] for stimulants, 0.83 [0.80,0.85] for anti-

depressants, and 0.79 [0.76,0.82] for anti-psychotics. Performance in external testing sets (HBN

and ABCD) confirmed generalizability. In the EMR cohort (PPP), AU-ROC were high: 0.90

[0.88,0.91] for anti-psychotics, 0.82 [0.92,0.83] for stimulants and 0.82 [0.80,0.84] for anti-

depressants.

Interpretation: This study demonstrates the feasibility of using AI to enhance medication

management for neurodivergent children, with expert clinician decisions learned with high

accuracy. These findings support the potential for AI decision aids in community settings,

promoting faster access to personalized care while highlighting the complexity of clinical and

sociodemographic factors influencing medication decisions.

Funding: Funding was provided by the Canadian Institutes of Health Research (Operating Grant

#527447) and Ontario Brain Institute.

Research in context

Evidence before this study: Current medication management practices for neurodevelopmental conditions, particularly for children who have not responded to first-line options, are based clinical best guess approaches that can have negative effects on children, their caregivers, and the health system. Precision health tools using artificial intelligence, which are suitable for community use, have the potential to improve the health system's capacity for providing timely and impactful care. We searched PubMed on October 17, 2024, for studies published in English evaluating artificial intelligence approaches for medication management in neurodivergence using the terms ("autism" OR "neurodevelopmental condition" OR "neurodevelopmental disorder" OR "neurodivergence") AND ("artificial intelligence" OR "machine learning" OR "deep learning" OR "prediction") AND ("medication management" OR "medication response" OR "medication appropriateness" OR "medication decision support") also including terms where "drug" is substituted for "medication". We did not find any relevant studies.

Added value of this study: This study demonstrates the feasibility of using AI to assist in medication management for neurodivergent children, with a strong ability to learn expert clinical decisions. These findings show AI may be able to support access to faster, more personalized treatment decisions regarding psychotropic medications. We also identified the relevant clinical and demographic features to the model's medication recommendations, as well as several biases with respect to sociodemographic factors, highlighting the complexity of factors that contribute to clinical decision-making.

Implications of all the available evidence: This work highlights AI's potential to improve medication management for neurodivergent children, by offering personalized treatment recommendations. However, identified biases underscore the need for addressing existing inequities. Future research should focus on prospective validation, integration into clinical practice, and bias mitigation to ensure equitable access to effective treatments for all children.

Introduction

Neurodevelopmental conditions, such as autism spectrum disorder (autism), intellectual disability (ID), and attention-deficit/hyperactivity disorder (ADHD), are highly heterogeneous and overlapping in their biology and phenotypic presentation[1,2], which includes hundreds of associated genes[3], and significant variability in neurobiological correlates[2]. Despite decades of research, no markers exist to indicate which biological pathway may be implicated for an individual child to guide individualized care[4,5], and current approaches to care provision remain reliant on broad diagnostic labels. This lack of precision is particularly challenging for pharmacological interventions in neurodevelopmental conditions. These interventions are highly prevalent with greater than 50% of children with neurodevelopmental conditions prescribed psychotropic medications to address behavioural and/or mental health concerns (e.g., anxiety, hyperactivity, aggressive or self-injurious behavior), and high rates of polypharmacy during childhood (~30%)[6].

Despite the prevalent use of psychotropic medications in neurodevelopmental conditions, there is tremendous variability in individual-level responses to psychotropic treatment for co-occurring mental health and behavioural condition[7], reflecting the heterogeneity of biological pathways impacted, diverse clinical presentations, as well as sociodemographic complexities that influence the acceptability and uptake of medications. This variability poses a significant challenge in determining the appropriate medication for an individual child, especially in cases where co-occurring conditions (e.g., autism, ADHD, anxiety) can interact and increase the complexity of presentation and response. In these cases, prescribing practices in the children and adolescents remain almost entirely off-label[6,8–12] and based on trial-and-error approaches that can expose children to multiple medication trials with the potential for severe and life-long adverse effects for some classes of medication[13]. This highlights the critical need for precision health tools that can provide medication recommendations based on an individual's unique presentation.

To fill this gap, we propose an artificial intelligence (AI) model that uses an individual's characteristics to predict the medication choice among the commonly prescribed classes in neurodivergence: stimulants, anti-depressants, and anti-psychotics. We first establish the

feasibility of this approach by building models to predict medication usage using a research

cohort of neurodivergent children and youth, using two international research cohorts for external

validation. Then, to examine how this approaches generalizes to real-world clinical settings, we

leveraged a patient cohort to predict continuation of a medication class after 3 months from

electronic medical record (EMR) data of neurodivergent children and youth who visited a

specialized psychopharmacology clinic.

Methods

Study design and cohorts

For the research cohorts, training and internal testing was conducted using data from 598

neurodivergent children and youth extracted from the Province of Ontario Neurodevelopmental

(POND) network (Ontario, Canada). External testing was performed using two international

cohorts: 1,764 neurodivergent children and youth from the Healthy Brain Network (HBN[14]; New

York, United States), and 2,396 neurodivergent children and youth from the Adolescent Brain

Cognitive Development study (ABCD[15]; United States).

For clinical validation, longitudinal EMRs from the Psychopharmacology Program (PPP) at

Holland Bloorview Kids Rehabilitation Hospital (Toronto, Ontario, Canada) were used. PPP sees

neurodivergent children who have tried at least one psychoactive medication without adequate

success. Data were extracted from electronic medical records of 312 children who visited the

PPP over a three-year period (2019 – 2022) and returned for a follow-up approximately 3 months

later.

Participant demographics are summarized in

Table 1. Further details on the cohorts, including eligibility and consent procedures, and a
comparison of the research cohorts can be found in the Supplementary Material. This study was
approved by the Research Ethics Board at Holland Bloorview Kids Rehabilitation Hospital.

Table 1. Cohort demographics and medication outcomes.

		Research cohorts			EMR cohort
		POND	**HBN**	**ABCD**	**PPP**
N		598	1,764	2,396	312
Age range (years)		5 – 19	5 – 17	8 – 11	4 – 17
Mean age [SD] (years)		11.4 [3.2]	10.1 [2.7]	9.9 [0.6]	10.4 [2.9]
Sex [%]	Male	424 [71]	1,213 [69]	1,523 [64]	262 [84]
	Female	174 [29]	5551 [31]	873 [36]	50 [16]
Autism [%]		338 [57]	325 [18]	0 [0]	292 [94]
ADHD [%]		193 [32]	1,381 [78]	1,751 [73]	181 [58]
OCD [%]		67 [11]	90 [5]	1,048 [44]	16 [5]
Intellectual disability [%]	Yes	84 [14]	86 [5]	149 [6]	105 [34]
	No	514 [86]	1,678 [95]	2,247 [94]	135 [43]
	Unknown	0 [0]	0 [0]	0 [0]	72 [23]
Race/ ethnicity [%]	White	327 [55]	871 [49]	1,257 [52]	NA
	Minoritized	156 [26]	866 [49]	1,137 [47]	NA
	Not collected	115 [19]	27 [2]	2 [1]	312 [100]
Annual household income [%]	Low	86 [14]	307 [17]	770 [32]	NA
	Medium	98 [16]	345 [20]	608 [25]	NA
	High	170 [28]	786 [45]	798 [33]	NA
	Not collected	244 [41]	326 [18]	220 [9]	312 [100]
Outcome [%]	Stimulant	171 [29]	177 [10]	551 [23]	114 [37]
	Anti-depressant	96 [16]	72 [4]	142 [6]	82 [26]
	Anti-psychotic	52 [9]	26 [1]	43 [2]	123 [39]

EMR: electronic medical record; PPP: Psychopharmacology Program; POND: Province of Ontario Neurodevelopmental network; HBN: Healthy Brain Network; ABCD: Adolescent Brain Cognitive Development study; SD: standard deviation; ADHD: attention-deficit/hyperactivity disorder; OCD: obsessive-compulsive disorder. For POND, primary diagnosis is reported; for ABCD, HBN, and PPP, refer to supplemental.

Predictors and outcome

For the PPP cohort, the set of predictors were co-created with the clinicians at the PPP program to reflect features relevant to the medication classes considered, and the availability of variables in the electronic medical records at the first visit. These predictors were broadly grouped into five categories: demographics, clinical, family-related, child-related, and care-related. The predicted outcome was the medication decision at the follow-up visit (

Table 1).

For the research cohorts, demographics (age and sex), neurodivergent diagnoses (autism,

ADHD, and OCD), IQ as a continuous score, and data from the Child Behaviour Checklist[16] were

used as predictors. The predicted outcome was the medication class the child was on at the time

of study (

Table 1). A full description of the predictors and outcome are presented in the

Supplementary Material.

Model

AI models were built to predict the outcome from the set of predictors, separately for

each medication class (Figure 1). For each model, 10 subsampling iterations were performed,

each using under-sampling to balance the dataset. For each subsample, five-fold cross-

validation was used to train and test the models. For the research cohorts, the models were

trained and internally tested using the POND dataset, while HBN and ABCD were withheld for

external testing. By validating with two external datasets, we assessed the generalizability and

robustness of the models, ensuring results are not specific to a single dataset and can be

replicated across diverse populations. For the EMR cohort (PPP), only internal testing was

performed.

Figure 1. Study design.

For the AI models, we used a stacked ensemble model implemented in Python (version

3.10) consisting of gradient boosting over decision trees (CatBoost[17]) and a two-layer deep neural

network (Keras[18] (version 3.7.0) with TensorFlow[19] (version 2.18.0)). Both models were trained

independently, and prediction probabilities were extracted. Then, a logistic regression model,

acting as a meta-learner, was used to combine the prediction probabilities from both models into

a final prediction, optimizing the ensemble's performance by leveraging the strengths of both

base models. This stacked ensemble was found to outperform other, simpler models (e.g.,

random forest).

Performance evaluation

Model performance was assessed using the area under the receiving operating

characteristic curve (AU-ROC), reporting means and 95% confidence intervals (CIs) across folds

and bootstrap subsamples. Additional metrics (area under the precision-recall curve (AU-PR),

sensitivity, and specificity) are provided in the Supplementary Material.

To interpret which features were most important for predicting longitudinal medication success,

Shapley Additive exPlanations (SHAP) values[20] were computed for the EMR (PPP) models. SHAP

values were computed for each of the base models and combined by taking their weighted

average using the coefficients from the logistic regression meta-learner.

The demographic parity ratio[21,22] was used to evaluate whether the model predictions

were independent of sensitive group status for sex, intellectual disability (ID), race/ethnicity, and

annual household income. The metric was computed at the default probability threshold (0.50)

across folds, bootstrap samples, and datasets for the research cohorts; the 80% rule was used

to determine any biases.

Role of the funding source

The funders of this study had no role in the collection, analysis, and interpretation or data,

in the writing of the report, nor in the decision to submit the report for publication.

Results

Model performance

The research cohorts demonstrated the feasibility of AI predicting treatment status cross-

sectionally for each medication class (Table 2 and Figure 2), with internal testing (POND)

demonstrating good-to-excellent AU-ROC that was significantly higher than chance for

stimulants (mean [95% CI]: 0.72 [0.71, 0.74]), anti-depressants (0.83 [0.80, 0.85]), and anti-

psychotics (0.79 [0.76, 0.82]). The performance of the external testing sets (HBN and ABCD)

indicated good generalizability, with the AU-ROCs slightly reduced but still in the good-to-

excellent range (except for anti-psychotics for ABCD).

Table 2. Model performance.

Mean AU-ROC [95% CI]	Research cohorts			EMR cohort
	Internal testing	External testing		Internal testing
	POND	HBN	ABCD	PPP
Stimulant	.72 [.71, .74]	.71 [.70, .71]	.70 [.70, .70]	.82 [.82, .83]
Anti-depressant	.83 [.80, .85]	.74 [.74, .75]	.66 [.65, .67]	.82 [.80, .84]
Anti-psychotic	.79 [.76, .82]	.77 [.76, .78]	.81 [.80, .82]	.90 [.88, .91]

EMR: electronic medical record; PPP: Psychopharmacology Program; POND: Province of Ontario Neurodevelopmental network; HBN: Healthy Brain Network; ABCD: Adolescent Brain Cognitive Development study; CI: confidence interval; AU-ROC: area under the receiving operating characteristic curve

Figure 2. ROC curves for the research cohorts, for the internal testing (A; POND) and external testing (B; HBN and ABCD) sets for each of the stimulant classes (green: stimulants, purple: anti-depressants, pink: anti-psychotics); AU-ROCs are also presented.

POND: Province of Ontario Neurodevelopmental network; HBN: Healthy Brain Network; ABCD: Adolescent Brain Cognitive Development study; ROC: receiving operating characteristic curve; AU-ROC: area under the ROC

165   For the EMR cohort (PPP; Table 2 and Figure 3A), the AU-ROC across the cross-validation

166   folds was outstanding for anti-psychotics (0.90 [0.88, 0.91]), and excellent for both stimulants

167   (0.82 [0.92, 0.83]) and anti-depressants (0.82 [0.80, 0.84]).

Figure 3. (A) ROC curves for the EMR cohort (PPP) for each of the stimulant classes (green: stimulants, purple: anti-depressants, pink: anti-psychotics); AU-ROCs are also presented. (B) Feature importance for the EMR cohort (PPP) assessed using SHAP values. The SHAP values are plotted for each participant for the 10 most important features for each medication class, sorted by importance (mean absolute SHAP value) from top to bottom. Colours represent the feature value (red for high values, blue for low values), indicating whether higher or lower values contribute positively or negatively to prediction scores.

EMR: electronic medical record; PPP: Psychopharmacology Program; ROC: receiving operating characteristic curve; AU-ROC: area under the ROC; SHAP: Shapley Additive exPlanations; ADHD: attention-deficit/hyperactivity disorder

Feature importance

SHAP values were computed for the EMR cohort (PPP), to identify which features were

most important for predicting medication choice (Figure 3B). Prior use of a medication class was

the most important feature across all four classes. In particular, prior use of a medication within

the same class, increased the likelihood of a medication choice in that class. Age was also a

salient feature: younger, middle, and older participants were more likely to be recommended

stimulants, anti-psychotics, and anti-depressants, respectively. Other important features

included ADHD and communication abilities for stimulants, anxiety and aggression for anti-

depressants, and burnout (indicated by treating physician) and current supports for anti-

psychotics.

Bias

The demographic parity ratio was computed to evaluate the bias of the models (Table 3),

where values exceeding 0.80 indicate bias according to the four-fifths rule[23]. For the research

cohorts, parity was generally high, with some exceptions with respect to anti-depressants and

anti-psychotics. Individuals who were female, did not have an intellectual disability (ID), and who

were white were more likely to be recommended an anti-depressant (male, female: 34%, 46%;

ID, no-ID: 26%, 39%; white, minority: 43%, 30%). On the other hand, males, those with an ID, and

those with a lower annual household income were more likely to be recommended anti-

psychotics (male, female: 46%, 35%; ID, no-ID: 72%, 38%; low, middle, high income: 55%, 35%,

32%). These observations extended to the EMR cohort, where individuals without an ID were also

more likely to be recommended stimulants (ID, no-ID: 27%, 63%). This was in line with trends in

the data.

Table 3. Demographic parity ratios for sensitive groups.

		Research cohorts	EMR cohort
Sex	Stimulant	0.87	0.93
	Anti-depressant	0.74	0.77
	Anti-psychotic	0.76	0.91
Intellectual disability	Stimulant	0.79	0.44
	Anti-depressant	0.67	0.71
	Anti-psychotic	0.52	0.59
Race/ethnicity	Stimulant	0.88	–
	Anti-depressant	0.70	–
	Anti-psychotic	0.95	–
Annual household income	Stimulant	0.93	–
	Anti-depressant	0.78	–
	Anti-psychotic	0.58	–

EMR: electronic medical record

Discussion

Medication management for neurodivergent children remains a significant challenge,

particularly in community settings where subspecialty expertise may not be available. To

address this gap, this study aimed to develop and evaluate an AI algorithm to predict

medication choices in neurodivergent children. Ultimately, this type of tool can be used as

a decision-aid to support medication management where specialized expertise are not
available.

We showed that AI can learn expert clinician medication decisions with high accuracy. We
also demonstrated that the results generalize across independent, international datasets, which
is notable given the drastically different characteristics of these cohorts, in terms of
demographics, diagnosis, phenotype, and region-specific access to service and supports (see
Supplemental Table 1 and Supplemental Table 2). While the accuracy in these research cohorts
is lower compared to the EMR model, this is likely due to the cross-sectional nature of the
prediction in these cohorts. For example, use of stimulant medications to target ADHD
behaviours confounds the measures of ADHD traits when considered cross-sectionally, in turn
impacting predictive performance.

Overall, these results support the feasibility of using an AI-based decision aid tool. This can
be particularly advantageous for community practitioners, where subspecialty expertise required
for medication management is often not available. Ultimately, an AI-based decision aid can bring
precision to current prescribing practices in the community which may expose children to
multiple medication trials that may have severe and life-long adverse effects[24]. Future trials,
prospective trials are needed to further validate this type of algorithms in clinical settings.

Explainability and interpretability are critical features of responsible AI systems, contributing
to enhancing trust and transparency with both clinicians and patients[25]. To promote
explainability, we characterized the relative contributions of clinical and demographic features to
the AI algorithm's medication recommendations. For the EMR cohort, these contributions were
closely aligned with indications for each medication class (e.g., simulants for ADHD, SSRIs for
anxiety, antipsychotics for irritability and aggression). Interestingly, the top contributors for all
classes were prior use of a medication in that class. This finding reflects the fact that medication
choices often remain within the same class of medication but entail changes in the medication
type and dosing within that class (e.g., amphetamines, methylphenidate within the stimulant
class). Future work will focus on adding this type of resolution to the AI predictions. Other

contributing features to medication decision reflected sociodemographic and environmental

factors that may contribute to clinical decision making beyond primary indications. For example,

family burnout, lack of other supports, and need for respite were significant contributors to the

decision to recommend an antipsychotic. These finding highlight the complexity of the clinical

and sociodemographic factors that contribute to value-laden decisions around medication

management for neurodivergent children.

Another aspect of responsible AI is potential algorithmic biases that may disproportionately

disadvantage subgroups of individuals. Our analysis revealed several biases including increased

recommendation of antipsychotics to children who were male, had intellectual disability, and

were from lower income households. On the other hand, anti-depressants recommendations

were increased for children who were female, did not have an intellectual disability, and who

were white. It is important to note that these biases are not related to any specific feature of the

AI algorithm, but mirror previously reported biases in prescription patterns which exist across the

system[26]. For example, decreased access to early diagnosis and behavioural interventions for

children from lower income household may contribute to a higher likelihood of crisis situations

that necessitate prescription of antipsychotic medications. Similarly, it is well established that

females are more vulnerable to anxiety and depression in adolescents[27], and depression can be

challenging to detect in individuals with an intellectual disability[28]. While computational

approaches to bias mitigation can be applied to equalize prescription rates for the AI algorithm,

these will not solve the underlying system-level inequities that impact children with marginalized

identities.

The results of this study should be interpreted considering several limitations. Firstly, for the

longitudinal prediction, we defined outcome as the medication choice at the follow-up visit.

Treatment success in neurodivergence is a complex, subjective, and value-laden construct. The

use of medication choice was co-created with clinicians as an outcome as it reflects the

aggregate effects of the multitude of factors contributing to a clinical decision to not stop a

medication (e.g., ineffectiveness, side-effects, acceptability or other factors). These children also

visited the specialized clinic after at least one psychoactive medication was tried without

success, and thus this may introduce biases when the models are used to make a first-line

medication decision. The models were trained using data exclusively from North America; future

work should investigate their translation to other global populations to account for potential

differences in healthcare systems, prescribing practices, and sociocultural influences on

mediation usage. Finally, this study exclusively focused on predicting medication classes; these

classes are broad, and future work should examine within-class predictability.

In summary, the present study focused on AI model development and evaluation,

demonstrating the feasibility of this approach for medication recommendation for neurodivergent

children. To enable effective clinical implication of this type of AI-tool, future studies are needed

to evaluate the algorithm in a prospective design at the point of care as well as acceptability, and

barriers and facilitators to uptake.

Declaration of interests

EA has received research funding from Roche and Anavex, consulting fees from Roche, Quadrant

Therapeutics, Ono, and Impel Pharmaceuticals, in-kind support from AMO Pharma and CRA-

Simons Foundation, royalties from APPI and Springer, an editorial honorarium from Wiley, and

has a patent for holly™. DB has received research funding from MapLight Therapeutics. MP has

received consulting fee from Addis & Associates/Roche, and MedCounsel. AK has a patent for

holly™ with royalties paid from Awake Labs and has received consulting fees from DNAStack and

Shaftesbury. The remaining authors have no conflicts to report.

Acknowledgements

Funding was provided by the Canadian Institutes of Health Research (Operating Grant #527447).

Acknowledgements for each of the research cohorts (POND, HBN, and ABCD) used in this study

are provided below.

POND: This research was conducted with the support of the Ontario Brain Institute (POND, PIs:

Dr. Evdokia Anagnostou and Dr. Jason P. Lerch), an independent non-profit corporation, funded

partially by the Ontario government. The opinions, results and conclusions are those of the

authors and no endorsement by the Ontario Brain Institute is intended or should be inferred.

HBN: This manuscript was prepared using a limited access dataset obtained from the Child Mind

Institute Biobank, the Healthy Brain Network (HBN). This manuscript reflects the views of the

authors and does not necessarily reflect the opinions or views of the Child Mind Institute.

ABCD: Data used in the preparation of this article were obtained from the Adolescent Brain

Cognitive DevelopmentSM (ABCD) Study (https://abcdstudy.org), held in the NIMH Data Archive

(NDA). This is a multisite, longitudinal study designed to recruit more than 10,000 children age 9-

10 and follow them over 10 years into early adulthood. The ABCD Study® is supported by the

National Institutes of Health and additional federal partners under award numbers

U01DA041048, U01DA050989, U01DA051016, U01DA041022, U01DA051018, U01DA051037,

U01DA050987, U01DA041174, U01DA041106, U01DA041117, U01DA041028, U01DA041134,

U01DA050988, U01DA051039, U01DA041156, U01DA041025, U01DA041120, U01DA051038,

U01DA041148, U01DA041093, U01DA041089, U24DA041123, U24DA041147. A full list of

supporters is available at https://abcdstudy.org/federal-partners.html. A listing of participating

sites and a complete listing of the study investigators can be found at

https://abcdstudy.org/consortium_members/. ABCD consortium investigators designed and

implemented the study and/or provided data but did not necessarily participate in the analysis or

writing of this report. This manuscript reflects the views of the authors and may not reflect the

opinions or views of the NIH or ABCD consortium investigators. The ABCD data repository grows

and changes over time. The ABCD data used in this report came from DOI: 10.15154/z563-zd24.

DOIs can be found at https://nda.nih.gov/abcd.

Data sharing statement

Data from four cohorts were used in this study, each governed by their own data sharing

restrictions. Full details can be found in the Supplementary Material.

Supplementary material

PPP

Dataset description

The clinical cohort used for this study was longitudinal electronic medical records from the Psychopharmacology Program (PPP) at Holland Bloorview Kids Rehabilitation Hospital (Toronto, Canada). The PPP is a program with provincial catchment in Ontario that provides medication management for neurodivergent children and youth. Children were eligible for this study if (1) their first visit was between 2019-2022, (2) they were at least four years of age at their first visit, and (3) they returned to the clinic for a follow-up visit. As the data was extracted from electronic medical records, no consent was obtained. Data from PPP is not publicly available due to ethics restrictions. Clinical data from all longitudinal clinical visits were extracted into a RedCap database from semi-structured medical record templates by trained chart reviewers. Two chart reviewers co-reviewed each medical record in sets of five and reviewed discrepancies until 85% agreement on all items was achieved. Reviewers proceeded independently after that, and any uncertainties were discussed with the study team.

Predictors

For PPP, the predictors were grouped into five categories: demographics, clinical, family-related, child-related, and care-related.

Demographic variables included age, sex (male or female), and region (urban (Toronto, General Toronto Area, or other Ontario city) or rural (rural or northern community)). Due to missing data, gender and race/ethnicity could not included as predictors. To capture socioeconomic status, whether a parent was receiving social assistance or means-tested disability support as a source of income was included as a predictor.

Clinical variables included neurodevelopmental diagnoses (attention-deficit/hyperactivity disorder (ADHD), autism, obsessive-compulsive disorder (OCD), intellectual disability, learning disorder, other psychiatric condition), mental health symptoms (anxiety, depression, irritability), and chronic conditions (epilepsy, cerebral palsy, asthma, migraines, gastroesophageal reflux disease, persisting constipation, obesity, and other).

Family-related factors included a family history of psychiatric or developmental

diagnoses in a first degree relative, and family reports of conflict between family members in the

household, caregiver burnout, and financial barriers to care, as reported by families and

documented by the treating clinician in the child's chart.

Child-related factors included school type (public, mainstream classroom, private,

mainstream classroom, public, specialized classroom, private, specialized classroom,

homeschool, or other), school attendance (full days, part days or withdrawal, frequent calls

home for pick-up, frequent school refusal or frequent absences, not attending or demitted from

school, or other), communication abilities (speaks fluidly in sentences, speaks a few words or

short phrases, non-speaking and uses communication technique, non-speaking and no other

formal communication form, and other). History of trauma (children's aid involvement,

witnessing violence, experiencing violence, physical abuse, sexual abuse, or neglect, other

significant stressor as perceived by the child, or other stressor), police involvement,

hospitalization, emergency department visits, intensive crisis service involvement due to

behavioural or mental health concerns, aggression, self-injury, and suicidal thoughts were also

included.

Care-related factors included receiving government funding for care (specifically, the

Ontario Assistance for Children with Severe Disabilities Program), which was coded as "yes",

"has not applied", "not eligible", or "other". Data on current, past, and recommended supports

were collected using the following categories: (1) behavioural therapy, Applied Behaviour

Analysis (ABA), or parent coaching by a behaviour therapist, (2) child therapy (e.g., Cognitive

Behavioural Therapy (CBT) or group therapy), (3) case management, (4) allied health, (5) respite,

(6) other, or (7) none. Prior use of five commonly prescribed medication classes (stimulants, non-

stimulants, hypnotics, anti-depressants, and anti-psychotics) was determined as whether a child

was taking a medication at the time of the first visit to the clinic. The behaviour that was targeted

for treatment at the first visit was collected using the following categories: physical aggression,

swearing/verbal threats, elopement, self-injury, verbal refusal, repetitive behaviours, property

destruction, tantrums/meltdowns, and/or other. Data on side effects reported at the first visit

were categorized as: headache, stomach-ache, constipation, nausea/vomiting, weight gain,

weight loss, irritability, drowsy/fatigue/sedation, insomnia, appetite decrease, appetite increase,

other, and/or none. Whether adherence problems for medications were discussed at the first

visit was also included as a predictor.

Outcome

The predicted outcome was the medication class choice at the follow-up visit (typically

scheduled 3 months after the first visit, with nursing support in between). While treatment

success in neurodivergence is a complex, subjective, and value-laden construct, the decision to

use this as an indicator of treatment success was co-created with PPP clinicians as it reflects the

aggregate effects of the multitude of factors contributing to a clinical decision to not stop a

medication (e.g., ineffectiveness, side effects, and acceptability).

Bias

Bias was assessed on sex (male versus female) and intellectual disability (yes versus no).

POND

Dataset description

The POND network is a research network spanning several institutions across Ontario,

Canada that collects demographic, phenotypic, and biological data from children and youth with

and without neurodevelopmental conditions. Participants were eligible for the current study if

they received a diagnosis of autism, ADHD, or OCD, if they were between 5 and 19 years of age,

and if diagnostic, medication usage, IQ, and the Child Behaviour Checklist (CBCL[16]) was

available. Children and youth provided written informed consent if they were able; otherwise,

they provided verbal assent, and their caregiver provided written consent. Data from POND is

managed by the Ontario Brain Institute and is available through a controlled data release. All

requests for access should be directed to the Brain-CODE platform

(https://www.braincode.ca/content/controlled-data-releases#dr006).

Predictors

Predictors for POND included demographics (age and sex), diagnosis (autism, ADHD, or

OCD), IQ, and the CBCL. Diagnoses were confirmed with expert clinical judgement alongside the

Autism Diagnostic Observation Schedule, 2 (ADOS-2[29]) and Autism Diagnostic Interview, Revised

(ADI-R[30]) for autism, the Parent Interview for Child Symptoms (PI/orCS[31]) and/or the Kiddie

Schedule for Affective Disorders and Schizophrenia (K-SADS[32]) for ADHD, and the Children's

Yale-Brown Obsessive-Compulsive Scale (YBOCS[33]) for OCD. Full-scale IQ was collected using

age-appropriate Wechsler[34–38] or Standford-Binet[39] scales. All the individual questions,

syndromic scale *T*-scores (anxious/depressed, withdrawn/depressed, somatic complaints,

social problems, thought problems, attention problems, rule-breaking behaviour, and aggressive

behaviour), and summary *T*-scores (internalizing problems, externalizing problems, and total

problems) from the CBCL were included as predictors.

Outcome

Caregivers were asked to provide a list of medication their child was taking. These

medications were classified as stimulants, non-stimulants, anti-depressants, and anti-

psychotics with assistance from clinicians. The predicted outcome was the medication class

reported.

Bias

Bias was be assessed for sex, intellectual disability, race/ethnicity, and socioeconomic

status. For sex, biological sex (male versus female) was used. Intellectual disability (yes versus

no) was determined using the full-scale IQ cutoff of 70. For race/ethnicity,

participants/caregivers were asked to select all groups that applied: Aboriginal, Arab, Black,

Chinese, East Asian, Filipino, Japanese, Korean, Latin American/Hispanic, South Asian,

Southeast Asian, West Asian, White, other; this data was used to categorize individuals as white

or minoritized. For socioeconomic status, we used annual household income categorized as low

(<\$50,000), middle (\$50,000-\$99,999), and high (≥\$100,000).

HBN

Dataset description

HBN is a mental health study of children and adolescents across the New York city

(United States) area that has collected demographic, phenotypic, and biological data; families

who had psychiatric concerns about their child were recruited for the study. Participants were

eligible for the current study if they received a diagnosis of autism, ADHD, or OCD, if they were

between 5 and 19 years of age, and if diagnostic, medication usage, IQ, and the CBCL[16] was

available. Participants at least 18 years of age provided written informed consent; otherwise, they

provided written assent, and their caregiver provided written consent. Access to the data used in

this study is protected by a Data Usage Agreement (DUA; see

https://fcon_1000.projects.nitrc.org/indi/cmi_healthy_brain_network for more details), which

was awarded to AK for this study.

Predictors

Aligning with POND, predictors for HBN included demographics (age and sex), diagnosis

(autism, ADHD, and/or OCD), full-scale IQ, and the CBCL. For diagnosis, the consensus DSM-5[40]

diagnoses provided by the HBN clinical team were used. Full-scale IQ was assessed using

Wechsler scales[37,38] or the Kaufman Brief Intelligence Test[41].

Outcome

Caregivers were asked to provide a list of medication their child had taken the day of the

visit. These medications were classified as stimulants, non-stimulants, anti-depressants, and

anti-psychotics with assistance from clinicians. The predicted outcome was the medication

class(es) the child was on.

Bias

Bias will be assessed on sex, intellectual disability, race/ethnicity, and socioeconomic

status. For sex, biological sex (male versus female) was used. Intellectual disability (yes versus

no) was determined using the full-scale IQ cutoff of 70. For race/ethnicity,

participants/caregivers indicated their ethnicity (not Hispanic or Latino, Hispanic or Latino,

decline to specify, or unknown) and race (White/Caucasian, Black/African American, Hispanic,

Asian, Indian, Native American Indian, American Indian/Alaskan Native, Native Hawaiian/Other

Pacific Islander, two or more races, or other race), which were used to categorize individuals as

white or minoritized. For socioeconomic status, we used annual household income categorized

as low (<$50,000), middle ($50,000-$99,999), and high (≥$100,000).

ABCD

Dataset description

The ABCD study[42] is a longitudinal study of adolescents from the general population

across the United States that has collected demographic, phenotypic, and biological data. For

the purposes of this study, only the first time point (collected at approximately 9-11 years of age)

was used. Participants were eligible for the current study if medication usage, IQ, the Kiddie

Schedule for Affective Disorders and Schizophrenia (K-SADS), and the CBCL was collected.

Caregivers provided written informed consent, and participants provided written assent. Access

to the data used in this study is protected by an NIMH Data Archive DUA for the Adolescent Brain

Cognitive Development (ABCD) permission group (see

https://nda.nih.gov/user/dashboard/data_permissions.html for more details), which was

awarded under DUA #15619 for this study.

Predictors

Aligning with POND, predictors for ABCD included demographics (age and sex), diagnosis

(autism, ADHD, and/or OCD), IQ, and the CBCL. Diagnoses were assigned using a computerized

version of the K-SADS[43] completed by parents and/or youth. IQ was assessed using the NIH

Toolbox[44] Cognition Battery's age-corrected total cognition composite score, which shows a high

degree of alignment with the Wechsler scales used in POND[45].

Outcome

Caregivers were asked to provide a list of medication their child had taken in the two

weeks preceding the visit. These medications were classified as stimulants, non-stimulants, anti-

depressants, and anti-psychotics with assistance from clinicians. The predicted outcome was

the probability a child was using the medication class.

Bias

Bias will be assessed on sex, intellectual disability, race/ethnicity, and socioeconomic

status. For sex, biological sex (male versus female) was used. Intellectual disability (yes versus

no) was determined using the IQ cutoff of 70. For race/ethnicity, participants/caregivers indicated

their race/ethnicity (Hispanic/Latino, non-Hispanic Asian, non-Hispanic Black, non-Hispanic

White, and Multi-Racial/Other), which were used to categorize individuals as white or

minoritized. For socioeconomic status, we used annual household income categorized as low

(<$50,000), middle ($50,000-$99,999), and high (≥$100,000).

Comparison of research cohorts

The demographic variables (age, sex, diagnosis, intellectual disability, race/ethnicity, and

socioeconomic status) were compared amongst the research cohorts (Supplemental Table 1).

Chi-squared tests were used for categorical variables, holding significance at $p<.050$ and

reporting Cramer's *v* effect sizes. ANOVAs or Kruskal-Wallis tests were used for continuous

variables, depending on normality, holding significance at $p<.050$, and reporting eta-squared

effect sizes.

Supplemental Table 1. Demographic comparison of the research cohorts.

Measure	Test-statistic	*p*-value	Effect size	Post-hocs
Age	95.07	<.001	.05	ABCD > POND > HBN
Sex	18.49	<.001	.06	Females: ABCD > POND, HBN
Autism	1,319.21	<.001	.53	POND > HBN > ABCD
ADHD	472.72	<.001	.32	HBN > ABCD > POND
OCD	871.51	<.001	.43	ABCD > POND > HBN
Intellectual disability	61.88	<.001	.11	POND > HBN, ABCD
Race/ethnicity	47.78	<.001	.10	White: POND > HBN, ABCD
Annual household income	131.50	<.001	.13	HBN > POND > ABCD

POND: Province of Ontario Neurodevelopmental network; HBN: Healthy Brain Network; ABCD: Adolescent Brain Cognitive Development study; ADHD: attention-deficit/hyperactivity disorder; OCD: obsessive-compulsive disorder

477　　　　　The CBCL summary *T*-scores were also compared amongst the datasets (Supplemental

478　Table 3), using ANOVAs or Kruskal-Wallis tests, depending on normality, holding significance at

479　$p<.050$, and reporting eta-squared effect sizes.

Supplemental Table 2. CBCL comparison of the research cohorts.

Measure	Median [IQR] ABCD	HBN	POND	Test statistic	*p*-value	Effect size	Post-hocs
Anxious/depressed	54 [50, 63]	55 [50, 64]	62 [53, 68]	120.64	<.001	.03	POND > HBN, ABCD
Withdrawn/depressed	54 [60, 52]	56 [50, 64]	60 [54, 68]	182.52	<.001	.04	POND > HBN > ABCD
Somatic complaints	57 [50, 64]	56 [50, 61]	57 [53, 64]	15.84	<.001	<.01	ABCD > POND, POND > HBN
Social problems	54 [51, 60]	58 [51, 64]	61 [54, 68]	244.41	<.001	.06	POND > HBN > ABCD
Thought problems	58 [51, 64]	58 [51, 67]	66 [58, 71]	216.91	<.001	.05	POND > HBN, ABCD
Attention problems	59 [53, 60]	64 [57, 69]	65 [59, 71]	264.73	<.001	.05	POND > HBN > ABCD
Rule-Breaking behaviour	53 [50, 60]	53 [51, 60]	54 [51, 62]	14.36	.001	<.01	ABCD > HBN, POND > ABCD
Aggressive behaviour	54 [50, 62]	57 [50, 66]	58 [51, 66]	73.53	<.001	.02	POND > HBN > ABCD
Internalizing problems	56 [48, 64]	57 [50, 65]	63 [55, 69]	143.27	<.001	.03	POND > HBN > ABCD
Externalizing problems	54 [46, 62]	56 [48, 65]	58 [50, 66]	53.60	<.001	.01	POND > HBN > ABCD
Total problems	56 [50, 64]	60 [52, 68]	64 [56, 70]	204.16	<.001	.04	POND > HBN > ABCD

CBCL: Child Behaviour Checklist; POND: Province of Ontario Neurodevelopmental network; HBN: Healthy Brain Network; ABCD: Adolescent Brain Cognitive Development study

480　***Performance evaluation***

481　Additional metrics (area under the precision-recall curve (AU-PR), sensitivity, and specificity) are

482　provided in the Supplementary Material.

Supplemental Table 3. Model performance.

	Research cohorts		Clinical cohort
	Internal testing	External testing	Internal testing

	POND	HBN	ABCD	PPP
Mean AU-PR [95% CI]				
Stimulant	.70 [.67, .72]	.68 [.68, .69]	.65 [.65, .66]	.86 [.86, .87]
Anti-depressant	.82 [.79, .84]	.75 [.74, .76]	.66 [.65, .67]	.84 [.82, .85]
Anti-psychotic	.81 [.78, .84]	.79 [.77, .81]	.81 [.80, .82]	.90 [.89, .92]
Mean sensitivity [95% CI]				
Stimulant	.72 [.70, .73]	.82 [.80, .83]	.77 [.76, .79]	.70 [.68, .72]
Anti-depressant	.73 [.70, .76]	.51 [.49, .52]	.44 [.41, .46]	.69 [.66, .72]
Anti-psychotic	.71 [.66, .76]	.60 [.57, .64]	.58 [.54, .61]	.83 [.68, .72]
Mean specificity [95% CI]				
Stimulant	.63 [.61, .65]	.46 [.44, .47]	.53 [.51, .54]	.78 [.77, .80]
Anti-depressant	.76 [.73, .79]	.83 [.82, .85]	.76 [.73, .78]	.80 [.78, .83]
Anti-psychotic	.71 [.66, .76]	.80 [.77, .84]	.86 [.84, .89]	.90 [.89, .92]

PPP: Psychopharmacology Program; POND: Province of Ontario Neurodevelopmental network; HBN: Healthy Brain Network; ABCD: Adolescent Brain Cognitive Development study; CI: confidence interval; AU-ROC: area under the receiving operating characteristic curve

References

Astle DE, Holmes J, Kievit R, Gathercole SE. Annual Research Review: The transdiagnostic revolution in neurodevelopmental disorders. *Journal of Child Psychology and Psychiatry* 2021; **n/a**. DOI:10.1111/jcpp.13481.

Vandewouw MM, Brian J, Crosbie J, *et al*. Identifying Replicable Subgroups in Neurodevelopmental Conditions Using Resting-State Functional Magnetic Resonance Imaging Data. *JAMA Network Open* 2023; **6**: e232066.

Trost B, Thiruvahindrapuram B, Chan AJS, *et al*. Genomic architecture of Autism Spectrum Disorder from comprehensive whole-genome sequence annotation. Genetic and Genomic Medicine, 2022 DOI:10.1101/2022.05.05.22274031.

Persico AM, Ricciardello A, Lamberti M, *et al*. The pediatric psychopharmacology of autism spectrum disorder: A systematic review - Part I: The past and the present. *Prog Neuropsychopharmacol Biol Psychiatry* 2021; **110**: 110326.

Lord C, Charman T, Havdahl A, *et al*. The Lancet Commission on the future of care and clinical research in autism. *Lancet* 2022; **399**: 271–334.

Feroe AG, Uppal N, Gutiérrez-Sacristán A, *et al*. Medication Use in the Management of Comorbidities Among Individuals With Autism Spectrum Disorder From a Large Nationwide Insurance Database. *JAMA Pediatrics* 2021; **175**: 957–65.

Baribeau D, Vorstman J, Anagnostou E. Novel treatments in autism spectrum disorder. *Curr Opin Psychiatry* 2022; **35**: 101–10.

Murray ML, Hsia Y, Glaser K, *et al*. Pharmacological treatments prescribed to people with autism spectrum disorder (ASD) in primary health care. *Psychopharmacology (Berl)* 2014; **231**: 1011–21.

Lake JK, Weiss JA, Dergal J, Lunsky Y. Child, parent, and service predictors of psychotropic polypharmacy among adolescents and young adults with an autism spectrum disorder. *J Child Adolesc Psychopharmacol* 2014; **24**: 486–93.

Spencer D, Marshall J, Post B, *et al*. Psychotropic medication use and polypharmacy in children with autism spectrum disorders. *Pediatrics* 2013; **132**: 833–40.

Mellahn OJ, Knott R, Tiego J, *et al*. Understanding the Diversity of Pharmacotherapeutic Management of ADHD With Co-occurring Autism: An Australian Cross-Sectional Survey. *Front Psychiatry* 2022; **13**: 914668.

Ritter C, Hewitt K, McMorris CA. Psychotropic Polypharmacy Among Children and Youth with Autism: A Systematic Review. *J Child Adolesc Psychopharmacol* 2021; **31**: 244–58.

Howes OD, Rogdaki M, Findon JL, *et al*. Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. *J Psychopharmacol* 2018; **32**: 3–29.

Alexander LM, Escalera J, Ai L, *et al*. An open resource for transdiagnostic research in pediatric mental health and learning disorders. *Sci Data* 2017; **4**: 170181.

Barch DM, Albaugh MD, Avenevoli S, *et al*. Demographic, physical and mental health assessments in the adolescent brain and cognitive development study: Rationale and description. *Dev Cogn Neurosci* 2018; **32**: 55–66.

Achenbach TM, Rescorla LA. Manual for the ASEBA school-age forms and profiles. Burlington, VT: University of Vermont Research Center for Children, Youth, and Families, 2001.

Prokhorenkova L, Gusev G, Vorobev A, Dorogush AV, Gulin A. CatBoost: unbiased boosting with categorical features. In: Proceedings of the 32nd International Conference on Neural Information Processing Systems. Red Hook, NY, USA: Curran Associates Inc., 2018: 6639–49.

Chollet F, others. Keras. 2015. https://keras.io.

Martín Abadi, Ashish Agarwal, Paul Barham, *et al*. TensorFlow: Large-Scale Machine Learning on Heterogeneous Systems. 2015. https://www.tensorflow.org/.

Lundberg SM, Lee S-I. A unified approach to interpreting model predictions. In: Proceedings of the 31st International Conference on Neural Information Processing Systems. Red Hook, NY, USA: Curran Associates Inc., 2017: 4768–77.

Bird S, Dudík M, Edgar R, *et al*. Fairlearn: A toolkit for assessing and improving fairness in AI. Microsoft, 2020 https://www.microsoft.com/en-us/research/publication/fairlearn-a-toolkit-for-assessing-and-improving-fairness-in-ai/.

Agarwal A, Beygelzimer A, Dudik M, Langford J, Wallach H. A Reductions Approach to Fair Classification. In: Dy J, Krause A, eds. Proceedings of the 35th International Conference on Machine Learning. PMLR, 2018: 60–9.

Holzer H, Neumark D. Assessing Affirmative Action. *Journal of Economic Literature* 2000; **38**: 483–568.

Howes OD, Rogdaki M, Findon JL, *et al*. Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. *J Psychopharmacol* 2018; **32**: 3–29.

Cutillo CM, Sharma KR, Foschini L, *et al*. Machine intelligence in healthcare-perspectives on trustworthiness, explainability, usability, and transparency. *NPJ Digit Med* 2020; **3**: 47.

Antoniou T, McCormack D, Kitchen S, *et al*. Geographic variation and sociodemographic correlates of prescription psychotropic drug use among children and youth in Ontario, Canada: a population-based study. *BMC Public Health* 2023; **23**: 85.

Shorey S, Ng ED, Wong CHJ. Global prevalence of depression and elevated depressive symptoms among adolescents: A systematic review and meta-analysis. *Br J Clin Psychol* 2022; **61**: 287–305.

Buckley N, Glasson EJ, Chen W, *et al*. Prevalence estimates of mental health problems in children and adolescents with intellectual disability: A systematic review and meta-analysis. *Aust N Z J Psychiatry* 2020; **54**: 970–84.

Lord C, Rutter M, DiLavore, P, Risi S, Gotham K, Bishop S. Autism diagnostic observation schedule: ADOS-2, 2nd edn. Los Angeles, CA: Western Psychological Services, 2012.

Rutter M, Le Couteur A, Lord C. Autism diagnostic interview revised. Los Angeles, CA: Western Psychological Services, 2003.

Ickowicz A, Schachar RJ, Sugarman R, Chen SX, Millette C, Cook L. The parent interview for child symptoms: a situation-specific clinical research interview for attention-deficit hyperactivity and related disorders. *Can J Psychiatry* 2006; **51**: 325–8.

Kaufman J, Birmaher B, Brent D, *et al*. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial reliability and validity data. *J Am Acad Child Adolesc Psychiatry* 1997; **36**: 980–8.

Scahill L, Riddle MA, McSwiggin-Hardin M, *et al*. Children's Yale-Brown Obsessive Compulsive Scale: Reliability and validity. *J Am Acad Child Adolesc Psychiatry* 1997; **36**: 844–52.

Wechsler D. Wechsler abbreviated scale of intelligence, 1st edn. San Antonio, TX: The Psychological Corporation, 1999.

Wechsler D. Wechsler preschool and primary scales of intelligence, 3rd edn. San Antonio, TX: The Psychological Corporation, 2002.

Wechsler D. Wechsler intelligence scale for children, 4th edn. San Antonio, TX: The Psychological Corporation, 2003.

Wechsler D. Wechsler abbreviated scale of intelligence, 2nd edn. San Antonio, TX: NCS Pearson, 2011.

Wechsler D. Wechsler intelligence scale for children, 5th edn. Bloomington, MN: Pearson, 2014.

Roid GH. Stanford-Binet intelligence scales, 5th edn. Itasca, IL: Riverside Publishing, 2003.

Diagnostic and statistical manual of mental disorders, 5th edn. Arlington, TX: American Psychiatric Association, 2013.

Kaufman AS, Kaufman NL. Kaufman Brief Intelligence Test, 2nd edn. Pearson.

Volkow ND, Koob GF, Croyle RT, *et al*. The conception of the ABCD study: From substance use to a broad NIH collaboration. *Dev Cogn Neurosci* 2018; **32**: 4–7.

Townsend L, Kobak K, Kearney C, *et al*. Development of Three Web-Based Computerized Versions of the Kiddie Schedule for Affective Disorders and Schizophrenia Child Psychiatric Diagnostic Interview: Preliminary Validity Data. *J Am Acad Child Adolesc Psychiatry* 2020; **59**: 309–25.

Weintraub S, Dikmen SS, Heaton RK, *et al*. Cognition assessment using the NIH Toolbox. *Neurology* 2013; **80**: S54-64.

Heaton RK, Akshoomoff N, Tulsky D, *et al*. Reliability and validity of composite scores from the NIH Toolbox Cognition Battery in adults. *J Int Neuropsychol Soc* 2014; **20**: 588–98.